Intuitive Surgical stock kpis
Want to see ISRG full AI Analyst Report?
Operating Expense Breakdown
Intuitive Surgical reported operating expenses of $1.49B in Q3 2026, up 50.9% from Q2 2026 and up 65.2% year over year. This is the highest value since 2018.
Details spending on R&D, sales and marketing, and general administration to show how the company is allocating cash; rising R&D and sales spend can fuel long-term growth but may pressure short-term profitability if not matched by revenue gains.
R&D has been accelerating faster than SG&A, signaling deliberate investment behind da Vinci 5, SP/XiR and ION — management explicitly said R&D will outpace SG&A. SG&A also trends up with pronounced December-quarter step‑ups tied to comp and seasonal costs; guidance for 11–13% non‑GAAP op‑expense growth and ~$880–$900M of noncash stock comp makes future quarters sensitive to timing. Investors should watch whether procedure/revenue momentum sustains to absorb higher R&D intensity and avoid margin pressure once one‑time items (tariff refund, Foundation gift) are excluded.
ISRG Operating Expense Breakdown
| Period | Research and Development | Selling, General, and Administrative | Total |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $408.30M | $1.08B | $1.49B |
| Q2 2026Jun 30, 2026 | $370.60M | $617.90M | $988.50M |
| Q1 2026Mar 31, 2026 | $361.90M | $613.30M | $975.20M |
| Q4 2025Dec 31, 2025 | $352.90M | $687.10M | $1.04B |
| Q3 2025Sep 30, 2025 | $329.40M | $573.30M | $902.70M |
| Q2 2025Jun 30, 2025 | $313.30M | $561.20M | $874.50M |
| Q1 2025Mar 31, 2025 | $316.20M | $563.40M | $879.60M |
| Q4 2024Dec 31, 2024 | $294.70M | $612.60M | $907.30M |
| Q3 2024Sep 30, 2024 | $286.00M | $510.60M | $796.60M |
| Q2 2024Jun 30, 2024 | $280.10M | $525.30M | $805.40M |
| Q1 2024Mar 31, 2024 | $284.50M | $491.50M | $776.00M |
| Q4 2023Dec 31, 2023 | $260.10M | $567.10M | $827.20M |
| Q3 2023Sep 30, 2023 | $249.40M | $452.00M | $701.40M |
| Q2 2023Jun 30, 2023 | $244.40M | $464.30M | $708.70M |
| Q1 2023Mar 31, 2023 | $244.90M | $480.50M | $725.40M |
| Q4 2022Dec 31, 2022 | $244.10M | $494.30M | $738.40M |
| Q3 2022Sep 30, 2022 | $217.10M | $436.10M | $653.20M |
| Q2 2022Jun 30, 2022 | $207.30M | $418.40M | $625.70M |
| Q1 2022Mar 31, 2022 | $210.50M | $391.10M | $601.60M |
| Q4 2021Dec 31, 2021 | $183.40M | $427.00M | $610.40M |
| Q3 2021Sep 30, 2021 | $165.50M | $363.30M | $528.80M |
| Q2 2021Jun 30, 2021 | $162.30M | $350.20M | $512.50M |
| Q1 2021Mar 31, 2021 | $159.80M | $326.00M | $485.80M |
| Q4 2020Dec 31, 2020 | $149.80M | $330.20M | $480.00M |
| Q3 2020Sep 30, 2020 | $155.00M | $298.90M | $453.90M |
| Q2 2020Jun 30, 2020 | $143.20M | $279.10M | $422.30M |
| Q1 2020Mar 31, 2020 | $147.10M | $308.10M | $455.20M |
| Q4 2019Dec 31, 2019 | $156.60M | $341.80M | $498.40M |
| Q3 2019Sep 30, 2019 | $135.90M | $284.00M | $419.90M |
| Q2 2019Jun 30, 2019 | $120.80M | $279.20M | $400.00M |
| Q1 2019Mar 31, 2019 | $144.00M | $273.40M | $417.40M |
| Q4 2018Dec 31, 2018 | $119.90M | $283.80M | $403.70M |
| Q3 2018Sep 30, 2018 | $107.60M | $221.40M | $329.00M |
| Q2 2018Jun 30, 2018 | $95.10M | $259.80M | $354.90M |
| Q1 2018Mar 31, 2018 | $273.40M | $221.60M | $495.00M |

